LYNPARZA |
AZ2281 |
AZD-2281 |
AZ-2281 |
KU-0059436 |
OLAPARIB |
AZD2281 |
KEYLYNK-010 COMPONENT OLAPARIB |
OLAPARIB COMPONENT OF KEYLYNK-010 |
KU-59436 |
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE |
KU59436 |
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE |
LYNPARZA® |
pubchem.compound:23725625 |
drugbank:09074 |
rxcui:1597582 |
chembl:CHEMBL521686 |
chemidplus:763113-22-0 |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (moderate) |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
FDA Approval | Ovarian cancer (with BRCA mutation) |
Drug Class | Small molecule inhibitor |
Drug Categories | bcrp/abcg2 inhibitors |
Drug Categories | cytochrome p-450 cyp2b6 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | immunosuppressive agents |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
n/a |
Indication/Tumor Type | ovarian cancer |
Response Type | sensitive |
Approval Status | Preclinical - Pdx |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PARP 1, 2 & 3 inhibitor |
Details of the Assay for Interaction | Assayed using PARP-2 isolated from HeLa cells, in a scintillation proximity ELISA. |
inhibitor (inhibitory) |
Mechanism of Interaction | PARP 1, 2 & 3 inhibitor |
Direct Interaction | yes |
Details of the Assay for Interaction | Assayed using PARP-1 isolated from HeLa cells, in a scintillation proximity ELISA. |
n/a |
Alteration | FANCA:del |
Drug family | PARP inhibitor |
Alteration | FANCA:. |
inhibitor (inhibitory) |
Mechanism of Interaction | PARP 1, 2 & 3 inhibitor |
Direct Interaction | yes |
n/a |
Alteration | BRCA1:. |
Drug family | PARP inhibitor |
Indication/Tumor Type | breast cancer |
n/a |
Alteration | ATR:del |
Alteration | ATR:. |
Drug family | PARP inhibitor |
n/a |
Drug family | PARP inhibitor |
Alteration | HDAC2:. |
n/a |
combination therapy | AZD6482 + Olaparib |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
OLAPARIB | DrugBank Drug Name |
763113-22-0 | CAS Number |
Lynparza | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antineoplastic agents |
AZD2281 | Development Name |
OLAPARIB | Generic Name |
LYNPARZA | Trade Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Ovarian cancer (with BRCA mutation) |
CHEMBL521686 | ChEMBL Drug ID |
D0J9HW | TTD Drug ID |
OLAPARIB | GuideToPharmacology Ligand Name |
OLAPARIB | Primary Drug Name |
OLAPARIB | Drug Generic Name |
AZD2281 | Drug Synonym |